Daxor Corporation Reports Increase in NAV to $7.08 Per Share and 31.8 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023
Daxor (DXR) reports a strong start to 2024 with unaudited revenue climbing 229.1% in the first two months of 2024 compared to the same period in 2023. The company's revenue increased by 31.8% in 2023 compared to 2022. The number of kits sold for their Diagnostic System rose by 36.2% in 2023. Daxor also launched 12 new accounts in 2023 and 6 new accounts in the first two months of 2024. The company anticipates breaking even within 12 months if FDA clearance for new units is obtained.
Positive
Strong revenue growth of 229.1% in the first two months of 2024 compared to 2023.
Revenue increased by 31.8% in 2023 compared to 2022.
36.2% increase in the number of kits sold for the Diagnostic System in 2023.
12 new accounts launched in 2023 and 6 new accounts in the first two months of 2024.
Management aims to break even within 12 months if FDA clearance for new units is obtained.
The considerable 229.1% increase in unaudited revenue for the first two months of 2024 compared to the same period in 2023 for Daxor Corporation is a significant indicator of growth, particularly when aligned with the 31.8% year-on-year revenue growth for 2023. This performance suggests a robust market demand for Daxor's blood volume measurement technology and an effective sales strategy, as indicated by the 36.2% rise in the number of kits sold. The company's ability to secure new accounts, both in 2023 and the beginning of 2024, reflects a strong commercial execution.
From a financial perspective, the increase in net asset value (NAV) from $6.75 to $7.08 over the fiscal year further implies a healthy financial position and operational efficiency. The partnerships with the U.S. Department of Defense and NIH funding are likely to provide stable revenue streams and could be a positive signal for investors looking for companies with diversified income sources. However, the forecasted break-even within 12 months is contingent on FDA clearance and continued sales growth, which introduces a degree of uncertainty that stakeholders should monitor closely.
Examining the broader market in which Daxor operates, the blood volume measurement technology sector is seeing increasing applications in clinical settings. The reported 95.7% increase in kit revenue for the early part of 2024 suggests that the company is capturing a larger share of this expanding market. This is further supported by the strategic addition of 12 new accounts in 2023 and 6 in the early months of 2024, which indicates an aggressive expansion and adoption of their technology.
Moreover, the anticipation of a new point-of-care system awaiting FDA approval could position Daxor at the forefront of innovation within the industry. This potential product launch might not only contribute to revenue growth but could also enhance the company's competitive edge. However, the actual impact will depend on the system's market reception and the timing of the FDA clearance. Stakeholders should consider the competitive landscape and the rate of technological adoption when evaluating Daxor's prospects.
Daxor's performance must be contextualized within the biotechnology sector's regulatory environment. The mention of pending FDA clearance for next-generation units is a critical factor that can significantly affect the company's trajectory. FDA approvals are notoriously unpredictable and any delays or rejections could impact the forecasted break-even and future revenue streams. It is essential for investors to understand the regulatory risks associated with biotech companies and the potential for stock volatility surrounding such announcements.
Additionally, the company's engagement with the U.S. Department of Defense and the National Institutes of Health not only diversifies its revenue but also aligns it with entities that can provide substantial funding for research and development. This could lead to further product innovation and a stronger patent portfolio, which are key drivers of long-term value in the biotech sector.
03/18/2024 - 02:18 PM
Strong Start to 2024 with Unaudited Revenue Climbing 229.1% in First Two Months of 2024 YoY
Oak Ridge, TN, March 18, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR) , the global leader in blood volume measurement technology, announces today the filing of its Annual Report to Shareholders on Form N-CSR, disclosing its schedule of portfolio holdings as of December 31, 2023.
Management reported a NAV of $7.08 per share for fiscal 2023 versus $6.75 for the comparable period in 2022.
The unaudited operating division reports the following highlights from its financial performance:
Revenue increased 31.8% Year on Year for 2023 versus 2022 Revenue in the first 2 months of 2024 has increased 229.1% Year on Year versus 2023 Number of Kits sold for our Diagnostic System rose 36.2% Year on Year for 2023 versus 2022 Kit revenue in the first 2 months of 2024 has increased 95.7% Year on Year versus 2023 12 New Accounts launched in 2023, combination of sales, rentals, and ezBVA Lab services 6 New Accounts in the first 2 months of 2024, combination of sales, lease, and ezBVA Lab services The operating company increased additional revenues to its commercial operations from the second half of 2023 with contracts from the U.S. Department of Defense, National Institutes of Health funding, and further sales of equipment warranty products. Management forecasts break-even for the operating company within 12-months if anticipated next generation units are cleared by FDA for sale, new contracts, and sales growth continues.
“We are pleased with our strong financial performance for fiscal 2023 driven by a combination of sold, leased, placed devices for commercial and research uses, and new lab services accounts, with eighteen new clients added. We have seen tremendous momentum coming into 2024 which is especially exciting as we get set to launch our newest point-of-care system when cleared by the FDA.”
Management has released more details from its operating division in a shareholder letter and intends to hold a shareholder meeting for further discussion of results.
About Daxor Corporation
Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100® (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com HERE
Forward-Looking Statements
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact: brets@coreir.com
What was the revenue growth percentage for Daxor (DXR) in the first two months of 2024 compared to 2023?
Daxor reported a revenue growth of 229.1% in the first two months of 2024 compared to the same period in 2023.
How much did the revenue increase in 2023 for Daxor (DXR) compared to 2022?
Daxor 's revenue increased by 31.8% in 2023 compared to 2022.
What was the percentage increase in the number of kits sold for the Diagnostic System by Daxor (DXR) in 2023?
The number of kits sold for the Diagnostic System by Daxor rose by 36.2% in 2023.
How many new accounts did Daxor (DXR) launch in 2023?
Daxor launched 12 new accounts in 2023.
How many new accounts did Daxor (DXR) launch in the first two months of 2024?
Daxor launched 6 new accounts in the first two months of 2024.
What is the management's forecast for Daxor (DXR) regarding breaking even?
Management anticipates Daxor breaking even within 12 months if FDA clearance for new units is obtained.
